Halozyme Therapeutics, Inc.
HALOHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHalozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and. With a market capitalization of $14.26B, it sits in large-cap territory. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Market Cap
$14.26B
Beta
0.88
P/E (TTM)
36.73
P/E (Fwd)
11.76
EPS (TTM)
$3.42
EPS (Fwd)
$10.68
ROE
173.7%
ROA
25.5%
Cash
$231.0M
Total Debt
$2.18B
Free CF
$337.3M
52W Change
90.8%
Annual Financials
Cash vs Debt
Where HALO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, HALO finished 46.15% above its 150-day moving average ($83.82) and 51.44% above its 200-day moving average ($80.89). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HALO overbought or oversold?
At the October 20, 2026 close, HALO's RSI(14) was 69.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, HALO has $231.0M in cash with $2.18B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $337.3M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 173.7%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 25.5% further supports the picture of efficient asset utilization. Revenue has grown from $660.1M (2022) to $1.40B (2025), reflecting a 112% increase over the period.
Halozyme Therapeutics, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Halozyme Therapeutics, Inc.'s trajectory.